NextCure, Inc. (NXTC): R&D Expense
$44.92M
Year ended 2025-12-31
$27.20M
Trailing 12 months to 2026-06-30
-6.1%
3-year compound annual growth
-0.7%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $44.92M | +8.3% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $41.49M | -13.4% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $47.93M | -11.6% | 2025-03-06, From 2023-01-01 |
| 2022-12-31 | $54.20M | +8.0% | 2024-03-21, From 2022-01-01 |
| 2021-12-31 | $50.19M | +7.8% | 2023-03-02, From 2021-01-01 |
| 2020-12-31 | $46.55M | +36.1% | 2022-03-03, From 2020-01-01 |
| 2019-12-31 | $34.22M | +72.9% | 2021-03-04, From 2019-01-01 |
| 2018-12-31 | $19.79M | n/a | 2020-03-12, From 2018-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| NextCure, Inc. (NXTC) | 2025-12-31 | $44.92M | +8.3% |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $30.81M | +14.8% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $16.73M | +41.0% |
| Unicycive Therapeutics, Inc. (UNCY) | 2025-12-31 | $9.12M | -54.4% |
| Hyperion Defi, Inc. (HYPD) | 2025-12-31 | $1.91M | -86.8% |
| Actinium Pharmaceuticals, Inc. (ATNM) | 2025-12-31 | $21.12M | -29.7% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $54.97M | +39.6% |
| Akari Therapeutics Plc (AKTX) | 2025-12-31 | $2.81M | -59.7% |
| Atossa Therapeutics, Inc. (ATOS) | 2025-12-31 | $21.18M | +50.1% |
Compare NXTC, IRD, COYA, UNCY side by side · Screen every company in Pharmaceutical Preparations ↗